Book a Meeting

Anti-CTLA-4 Antibody, ADCC Enchanced (CAT#: BioBet-CB-012LX) Datasheet

Target
CTLA-4
Isotype
IgG1
Description
Anti-CTLA-4 Antibody, ADCC Enchanced (BioBet-CB-012LX) is a glycosylation-modified anti-CTLA-4 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CTLA-4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CTLA-4
Full Name
cytotoxic T-lymphocyte associated protein 4
Background
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
Alternative Names
CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
Gene ID
1493
UniProt ID
P16410
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-012LX
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CTLA-4 (Zalifrelimab) Antibody is derived from clone Zalifrelimab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CTLA-4, and it is intended for the research of Cervical cancer.
Antibody Indication
Cervical cancer

Cervical cancer

Related Products

Anti-CTLA-4 Antibody, Recycling (CAT#: AES-0622-ZP150)
ADCC-Enhanced Anti-Human CTLA-4 (Tremelimumab) Antibody (CAT#: BioBet-CB-015LX)
Non-Fucosylated Anti-Human CTLA-4 (AGEN 1884) Therapeutic Antibody (CAT#: BioBet-1725ZP)
Anti-CTLA-4 Antibody, Highly Galactosylated (CAT#: BioBet-GA-027ZP)
ADCC-Enhanced Anti-Human CTLA-4 (IBI310) Antibody (CAT#: BioBet-CB-032LX)
Anti-CTLA-4 Antibody, Non-Fucosylated (CAT#: BioBet-027ZP)
Anti-CTLA-4 Antibody, FcγRIIB Binding Enhanced (CAT#: AES-0622-ZP478)
Anti-CTLA-4 Antibody, On-Target (CAT#: AES-0622-ZP806)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.